148 related articles for article (PubMed ID: 31102417)
1. Impact of delayed radioiodine therapy in intermediate-/high-risk papillary thyroid carcinoma.
Kim M; Han M; Jeon MJ; Kim WG; Kim IJ; Ryu JS; Kim WB; Shong YK; Kim TY; Kim BH
Clin Endocrinol (Oxf); 2019 Sep; 91(3):449-455. PubMed ID: 31102417
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis.
Ahn J; Jin M; Song E; Jeon MJ; Kim TY; Ryu JS; Kim WB; Shong YK; Han JM; Kim WG
Endocrinol Metab (Seoul); 2020 Dec; 35(4):830-837. PubMed ID: 33202517
[TBL] [Abstract][Full Text] [Related]
3. Radioactive Iodine Therapy Decreases the Recurrence of Intermediate-Risk PTC With Low Thyroglobulin Levels.
Tian T; Qi Z; Huang S; Wang H; Huang R
J Clin Endocrinol Metab; 2023 Jul; 108(8):2033-2041. PubMed ID: 36715264
[TBL] [Abstract][Full Text] [Related]
4. Effect of Waiting Time for Radioactive Iodine Therapy on Outcome in N1 Stage Papillary Thyroid Cancer.
Sun Y; Sun Q; Tian J; He X
J Clin Endocrinol Metab; 2023 Oct; 108(11):e1413-e1423. PubMed ID: 37167097
[TBL] [Abstract][Full Text] [Related]
5. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
Simões-Pereira J; Ferreira TC; Limbert E; Cavaco BM; Leite V
Thyroid; 2021 Oct; 31(10):1514-1522. PubMed ID: 34155923
[No Abstract] [Full Text] [Related]
7. Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.
Wenter V; Jellinek A; Unterrainer M; Ahmaddy F; Lehner S; Albert NL; Bartenstein P; Knösel T; Spitzweg C; Ilhan H; Todica A
Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2526-2535. PubMed ID: 31410542
[TBL] [Abstract][Full Text] [Related]
8. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
9. Impact factors for the outcome of the first
Shangguan L; Fang S; Zhang P; Han S; Shen X; Geng Y; Luo D; Zhao C
Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
[TBL] [Abstract][Full Text] [Related]
10. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
Chandekar KR; Satapathy S; Bal C
Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
[TBL] [Abstract][Full Text] [Related]
11. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
[TBL] [Abstract][Full Text] [Related]
13. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
[TBL] [Abstract][Full Text] [Related]
14. Factors Influencing the Success of the First Radioiodine Therapy for Differentiated Thyroid Carcinoma.
Claimon A; Pusuwan P; Khiewvan B
J Med Assoc Thai; 2017 Feb; 100(2):207-18. PubMed ID: 29916638
[TBL] [Abstract][Full Text] [Related]
15. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
[TBL] [Abstract][Full Text] [Related]
16. The impact of iodinated contrast agent administered during preoperative computed tomography scan on body iodine pool in patients with differentiated thyroid cancer preparing for radioactive iodine treatment.
Sohn SY; Choi JH; Kim NK; Joung JY; Cho YY; Park SM; Kim TH; Jin SM; Bae JC; Lee SY; Chung JH; Kim SW
Thyroid; 2014 May; 24(5):872-7. PubMed ID: 24295076
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Delayed Surgery and Clinical Outcomes in Intermediate- and High-risk Papillary Thyroid Cancer.
Zhou H; Wu J; Shi L; Wang Y; Liu B
J Clin Endocrinol Metab; 2022 Nov; 107(12):3389-3397. PubMed ID: 36056633
[TBL] [Abstract][Full Text] [Related]
18. Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis.
Liu J; Zhang Z; Huang H; Xu S; Liu Y; Liu S; Wang X; Xu Z
Oral Oncol; 2019 Mar; 90():17-22. PubMed ID: 30846171
[TBL] [Abstract][Full Text] [Related]
19. Minimal Extrathyroidal Extension in Predicting 1-Year Outcomes: A Longitudinal Multicenter Study of Low-to-Intermediate-Risk Papillary Thyroid Carcinoma (ITCO#4).
Forleo R; Grani G; Alfò M; Zilioli V; Giubbini R; Zatelli MC; Gagliardi I; Piovesan A; Ragni A; Morelli S; Puxeddu E; Pagano L; Deandrea M; Ceresini G; Torlontano M; Puligheddu B; Antonelli A; Centanni M; Fugazzola L; Spiazzi G; Monti S; Rossetto R; Monzani F; Tallini G; Crescenzi A; Sparano C; Bruno R; Repaci A; Tumino D; Pezzullo L; Lombardi CP; Ferraro Petrillo U; Filetti S; Durante C; Castagna MG
Thyroid; 2021 Dec; 31(12):1814-1821. PubMed ID: 34541894
[No Abstract] [Full Text] [Related]
20. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
